BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cannabidiol (JZP926) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cannabidiol (JZP926)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07723963-8942@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Cannabidiol (JZP926): Phase 2/3 readout est. (NCT07723963)
DESCRIPTION:Cannabidiol (JZP926)\, phase 2/3\, Epilepsy.\nStudy: A Study to
  Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of J
 uvenile Myoclonic Epilepsy\nEstimated primary completion: 1 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cannabidiol-jzp926#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772396
 3
URL:https://assetmemo.bio/drug/cannabidiol-jzp926#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
